1. Home
  2. RKTO vs ALLR Comparison

RKTO vs ALLR Comparison

Compare RKTO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket One Inc. Common Stock

RKTO

Rocket One Inc. Common Stock

N/A

Current Price

$0.68

Market Cap

18.9M

Sector

Health Care

ML Signal

N/A

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

N/A

Current Price

$1.36

Market Cap

21.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RKTO
ALLR
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
21.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
RKTO
ALLR
Price
$0.68
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
299.6K
70.9K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
29.69
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.77
52 Week High
$1.19
$1.92

Technical Indicators

Market Signals
Indicator
RKTO
ALLR
Relative Strength Index (RSI) 33.28 56.83
Support Level N/A $1.22
Resistance Level $0.78 $1.42
Average True Range (ATR) 0.03 0.09
MACD -0.00 0.00
Stochastic Oscillator 18.23 70.00

Price Performance

Historical Comparison
RKTO
ALLR

About RKTO Rocket One Inc. Common Stock

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: